Resolution of vulvitis circumscripta plasmacellularis with topical imiquimod: two case reports

Ee, Hock Leong; Yosipovitch, Gil; Chan, Roy; Ong, Biauw Chi

doi:10.1046/j.1365-2133.2003.05583.x

Cited by 22 publications

(31 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean age at onset of vulvar lichen sclerosus (VLS) in our population was about 49 years, which is consistent with other reports, although the condition has been reported in the third to ninth decade of life [1,2,3,4,5] and a unique case has been described in an 8-year-old-girl [25]. …”

Section: Discussionsupporting

confidence: 91%

“…The incidence of PCV is unknown, as well as its aetiopathogenesis, although a variety of triggering factors have been hypothesized [1,2,3,4,5,19]. The presence of a lichenoid infiltrate containing a predominance of plasma cells as a distinctive histological marker suggests a polyclonal stimulation of B cells [23].…”

Section: Discussionmentioning

confidence: 99%

“…It is an entirely benign disorder, but it can cause local discomfort and render differential diagnosis with other vulvar disorders difficult [1,2,3,4,5]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Symptoms in Plasma Cell Vulvitis: First Observational Cohort Study on Type, Frequency and Severity

Corazza

Minghetti

Borghi³

2015

Dermatology

View full text Add to dashboard Cite

Background: Studies assessing symptoms of plasma cell vulvitis (PCV) are lacking. Objectives: To assess the prevalence and severity of PCV-related symptoms and identify possible associations between patient characteristics, clinical features of PCV and treatments administered before a definitive diagnosis. Methods: Thirty-six patients affected with PCV were included. Data were collected by direct interview and clinical examination. Results: Thirty patients (83.3%) complained of symptoms: burning was the most frequent (80.6%) while dyspareunia was the severest. Of the symptomatic patients, 73.3% experienced severe symptoms. Severity of symptoms was not associated with age at onset and duration of PCV. Almost 70% of the patients had previously undergone treatments. Conclusions: Symptoms in PCV are frequent and more than often severe. Neither age at onset nor duration of the disease nor the extent of vulvar involvement were associated with symptom severity. Both the delay in diagnosis and the inappropriate previous treatments seem to indicate frequent misdiagnosis.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Symptoms in Plasma Cell Vulvitis: First Observational Cohort Study on Type, Frequency and Severity

Corazza

Minghetti

Borghi³

2015

Dermatology

View full text Add to dashboard Cite

show abstract

“…Contrary to the more common symptomless corresponding male condition, women often complain of pruritus, burning, pain, dysuria and dyspareunia; so, many therapies have been tried to reduce vulvar discomfort, but the disease tends to relapse [7, 10]. As the new immunomodulating topical agent, tacrolimus, has been successfully employed in a wide range of genital inflammatory diseases [11,12,13,14,15,16,17,18,19,20], including a few cases of relapsing Zoon’s balanitis [21,22,23], we used tacrolimus 0.1% ointment in a small group of patients affected by plasma cell vulvitis.…”

Section: Introductionmentioning

confidence: 99%

Tacrolimus 0.1% Ointment: Is It Really Effective in Plasma Cell Vulvitis?

Mantovani¹,

Lauriola²,

Marzola³

et al. 2008

Dermatology

View full text Add to dashboard Cite

Background: Plasma cell vulvitis is a clinically and histologically well-characterized chronic disease that usually relapses after various topical therapies. Considering the inflammatory nature of the disease, the new topical calcineurin inhibitors have been also employed successfully in few cases of Zoon’s balanitis, the corresponding male condition. Objective: The aim of our study is to evaluate the effectiveness of tacrolimus ointment in a small group of plasma cell vulvitis sufferers. Methods: 4 women affected by biopsy-proved plasma cell vulvitis were enrolled, after informed consent. The topical drug was applied twice daily for 6 weeks, then tapered on the basis of the clinical results. Symptoms and objective parameters were obtained periodically at the beginning, after 6 weeks and up to the end of the topical treatment. A final biopsy was performed in 3 out of our 4 patients. The follow-up is still ongoing. Results: The comparative analysis of subjective, objective and histopathological data has shown discordant and less encouraging results than those reported for the corresponding male condition. Conclusion: At the moment, topical tacrolimus could be considered an alternative treatment for plasma cell vulvitis only in cases resistant to conventional therapies.

show abstract

“…The patient with complete resolution had to stop treatment after 16 weeks due to onset of pruritus and burning. In another case series, two patients applied imiquimod 3-7 times weekly for at least 2 months [15]. One remained disease free at 6 months of follow up and the other required 1 month of therapy after a recurrence.…”

Section: Case Reportmentioning

confidence: 99%

Plasma Cell Vulvitis: A Case Report and Review of Literature

A¹

2015

J Women’s Health Care

View full text Add to dashboard Cite

Plasma cell vulvitis (PCV) is a rare disease affecting anogenital skin. It is also known by multiple names including Zoon's vulvitis and vulvitis circumscripta plasmacellularis. It is an inflammatory condition that can cause severe local discomfort and psychosocial distress. The diagnosis is challenging and often remains unrecognized. It usually presents as a glistening, red, well-demarcated plaque or patch. The pathophysiology is unknown. Treatment recommendation is mostly based on case reports and case series and this condition is often recalcitrant to topical and systemic treatment.

show abstract

Resolution of vulvitis circumscripta plasmacellularis with topical imiquimod: two case reports

Cited by 22 publications

References 14 publications

Symptoms in Plasma Cell Vulvitis: First Observational Cohort Study on Type, Frequency and Severity

Symptoms in Plasma Cell Vulvitis: First Observational Cohort Study on Type, Frequency and Severity

Tacrolimus 0.1% Ointment: Is It Really Effective in Plasma Cell Vulvitis?

Plasma Cell Vulvitis: A Case Report and Review of Literature

Contact Info

Product

Resources

About